Patents by Inventor Jonathan D. Port

Jonathan D. Port has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions involving (S)-bucindolol
    Patent number: 11452712
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 27, 2022
    Assignee: Arca Biopharma Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL
    Publication number: 20190358204
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Application
    Filed: December 13, 2018
    Publication date: November 28, 2019
    Inventors: Michael R. Bristow, Jonathan D. Port
  • METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL
    Publication number: 20180161309
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Application
    Filed: September 18, 2017
    Publication date: June 14, 2018
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Methods and compositions involving (S)-bucindolol
    Patent number: 9763916
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 19, 2017
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Methods and Compositions Involving (S)-Bucindolol
    Publication number: 20170000766
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 5, 2017
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Methods and compositions involving (S)-bucindolol
    Patent number: 9446023
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: September 20, 2016
    Assignee: ARCA Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL
    Publication number: 20150190375
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention.
    Type: Application
    Filed: January 6, 2015
    Publication date: July 9, 2015
    Inventors: Michael R. Bristow, Jonathan D. Port
  • Methods and compositions involving (S)-bucindolol
    Patent number: 8946284
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. Formula (I).
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: February 3, 2015
    Assignee: Arca Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port
  • METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL
    Publication number: 20120108617
    Abstract: Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. Formula (I).
    Type: Application
    Filed: January 27, 2009
    Publication date: May 3, 2012
    Applicant: Arca Biopharma, Inc.
    Inventors: Michael R. Bristow, Jonathan D. Port